Multidisciplinary Journal of Science and Technology

CLINICAL PHARMACOLOGICAL APPROACH TO THE USE OF NEUROLEPTIC DRUGS IN DEPRESSIVE SYNDROME

Akhmedov Bahodir

Assistant intern of the Department of Pharmacology, Clinical Pharmacology and Medical Biotechnology, ASMI

Keywords: neuroleptics, depressive syndrome, antipsychotics, pharmacology, dopamine antagonists, serotonin modulation.

Abstract

The clinical use of neuroleptic (antipsychotic) drugs in depressive syndromes represents a complex intersection between psychopharmacology and clinical psychiatry. Traditionally employed in the management of psychotic disorders, certain neuroleptic agents have demonstrated significant efficacy as adjuncts or augmenting agents in depressive disorders, particularly those resistant to conventional antidepressant therapy. Their pharmacological effects extend beyond dopamine receptor antagonism, encompassing modulation of serotonergic, noradrenergic, and glutamatergic neurotransmission. This article examines the pharmacodynamics, pharmacokinetics, clinical applications, and safety considerations of neuroleptic drugs in depressive syndromes, highlighting both their therapeutic potential and the challenges associated with their use.

References

1. Stahl, S. M. Essential Psychopharmacology: Neuroscientific Basis and Practical Applications. Cambridge University Press, 2021.

2. Nelson, J. C., & Papakostas, G. I. Atypical antipsychotic augmentation in major depressive disorder: a meta-analysis. American Journal of Psychiatry, 2019.

3. Citrome, L. Adjunctive antipsychotic use in depression: pharmacological rationale and evidence-based review. International Journal of Neuropsychopharmacology, 2017.

4. Kato, M., et al. Pharmacogenomics in the treatment of major depressive disorder: implications for antipsychotic augmentation. Molecular Psychiatry, 2019.

5. Thase, M. E., et al. Quetiapine XR in major depressive disorder: efficacy and safety in randomized clinical trials. Journal of Clinical Psychiatry, 2010.